Abstract:Objective To investigate the efficacy of sunitinib in the treatment of patients with imatinibresistant advanced gastrointestinal stromal tumor (GIST).Methods The clinical data of 45 patients with imatinib-resistant advanced GIST who received the treatment of sunitinib (37.5 mg/d) at the First Affiliated Hospital of Sun Yat-Sen University from March 2008 to June 2012 were retrospectively analyzed.The mutation of c-kit and platelet-derived growth factor receptor α (PDGFRα) was detected,and the efficacy of imatinib was assessed after the treatment for 3 months,and factors influencing the survival were analysed.The survival rate was calculated using the Kaplan-Meier method,survival analysis was done using the one-way analysis of variance,and multivariate analysis was done using the COX regression model.Results The median time of treatment with sunitinib for the 45 patients was 11.0 months (range,4-37 months).The complete remission rate,partial response rate,rate of stabilized condition and disease progression rate were 15.6％ (7/45),8.9％ (4/45),46.7％ (21/45) and 28.9％ (13/45) after the treatment with sunitinib for 3 months.All the patients with clinical (imaging) complete remission received surgery for metastatic lesions or B-ultrasound guided ablation for single liver metastasis before the treatment with sunitinib.The most common grade 3 or 4 adverse reactions of sunitinib were hand-foot syndrome and anemia.C-kit and PDGFRα mutational analysis were carried out.C-kit exon 9 mutation was detected in 9 patients,c-kit exon 11 mutation in 21 patients,and no mutation was detected in 12 patients.The median progression-free survival time was 8.0 months (range,4.1-11.9 months),and the median overall survival time was 25.0 months (range,13.4-36.6 months).The results of univariate analysis showed that the primary lesion sites and mutational status of primary lesions were factors influencing the progression-free survival and overall survival (x2=5.967,6.622 ; 7.965,8.765,P ＜ 0.05).The results of multivariate analysis showed that only the mutational status of c-kit of primary lesions was the independent factor influencing the progression-free survival and overall survival (Wald =6.540,7.205,P ＜ 0.05).The progression-free survival and overall survival of patients with c-kit exon 9 mutation and patients with no gene mutation were significantly longer than patients with c-kit exon 11 mutation (x2 =7.965,8.765,P ＜ 0.05).Conclusion Sunitinib with a dosage of 37.5 mg/d could effectively treat patients with imatinib-resistant advanced GIST.A better survival is observed in patients with c-kit exon 9 mutation or with no gene mutation when compared with patients with c-kit exon 11 mutation.

Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib: A systematic review.

Relationship Between Efficacy of Sunitinib and KIT Mutation of Patients with Advanced Gastrointestinal Stromal Tumors after Failure of Imatinib

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Followed by Sunitinib Compared to Followed by Imatinib-a Multi-Center Cohort Study

Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review

A Multicenter Cohort Study of Sunitinib (SU) Versus Imatinib (IM) Dose Escalation As Second-Line Therapy in Patients with Gastrointestinal Stromal Tumors (gists) after Disease Progression of 400 Mg/d IM.

Clinical Outcomes of Imatinib Dose Escalation Versus Sunitinib in First-Line Imatinib-Failure Gastrointestinal Stromal Tumour

Application of Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumor

[Secondary Mutation of C-Kit/pdgfrα Genotypes after Imatinib Mesylate Therapy and Its Relationship with Efficacy of Sunitinib].

Secondary Mutations of C-Kit Contribute to Acquired Resistance to Imatinib and Decrease Efficacy of Sunitinib in Chinese Patients with Gastrointestinal Stromal Tumors

Practical Role Of Mutation Analysis For Imatinib Treatment In Patients With Advanced Gastrointestinal Stromal Tumors: A Meta-Analysis

Efficacy and Safety of Sunitinib in Chinese Patients with Imatinib-Resistant or -Intolerant Gastrointestinal Stromal Tumors.

Development of Sunitinib in the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

Clinical Benefit of Sunitinib in Gastrointestinal Stromal Tumors with Different Exon 11 Mutation Genotypes

Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors - a real-world multi-center study

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure

Clinical Analysis of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor

[Effect of C-Kit Mutation on the Prognosis of Gastrointestinal Stromal Tumors: a Meta-Analysis].

C-KIT Mutations Were Closely Associated with the Response to Imatinib in Chinese Advanced Gastrointestinal Stromal Tumor Patients.

Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.

Preclinical model-based evaluation of Imatinib resistance induced by <i>KIT</i> mutations and its overcoming strategies in gastrointestinal stromal tumor (GIST)